Prelude Capital Management, LLC Chemo Centryx, Inc. Transaction History

Prelude Capital Management, LLC

$1.57 Billion
Q3 2024

Shares

12 transactions

Quarter	Operation	Price Per share	shares change	shares Held	SEC Form
Q3 2022 Nov 14, 2022	BUY	$22.17 - $51.8 $4.25 Million - $9.93 Million	191,661 Added 1114.31%	208,861 $10.8 Million
Q2 2022 Aug 15, 2022	BUY	$15.36 - $27.51 $264,192 - $473,172	17,200 New	17,200 $426,000
Q1 2022 May 16, 2022	SELL	$22.22 - $39.12 $411,070 - $723,720	-18,500 Closed	0 $0
Q4 2021 Feb 14, 2022	BUY	$18.38 - $40.5 $340,030 - $749,250	18,500 New	18,500 $674,000
Q3 2019 Nov 14, 2019	SELL	$6.47 - $8.96 $3,694 - $5,116	-571 Closed	0 $0
Q2 2019 Aug 14, 2019	BUY	$8.31 - $14.85 $4,745 - $8,479	571 New	571 $5,000
Q1 2019 May 15, 2019	SELL	$10.01 - $13.89 $10,770 - $14,945	-1,076 Closed	0 $0
Q3 2018 Nov 14, 2018	BUY	$10.49 - $13.72 $11,287 - $14,762	1,076 New	1,076 $14,000
Q2 2018 Aug 14, 2018	SELL	$10.62 - $13.98 $10,439 - $13,742	-983 Closed	0 $0
Q1 2018 May 15, 2018	BUY	$5.9 - $14.99 $5,799 - $14,735	983 New	983 $13,000
Q4 2017 Feb 14, 2018	SELL	$5.53 - $8.42 $2,765 - $4,210	-500 Closed	0 $0
Q3 2017 Nov 14, 2017	BUY	$6.5 - $10.69 $3,250 - $5,345	500	500 $4,000

Others Institutions Holding CCXI

# of Institutions

6

Shares Held

66.3K

Call Options Held

0

Put Options Held

0

About ChemoCentryx, Inc.

Ticker CCXI
Exchange NASDAQ
Shares Outstandng 71,919,696
Market Cap $3.68M
Description
ChemoCentryx, Inc., a biopharmaceutical company, focuses on the development and commercialization of new medications for inflammatory disorders, autoimmune diseases, and cancer in the United States. It offers TAVNEOS (avacopan), an orally administered selective C5aR inhibitor for the treatment of adult patients with severe active anti-neutrophil...

More about CCXI

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Prelude Capital Management, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Prelude Capital Management, LLC with notifications on news.